RxDoctor Payments Data

Franklin Polun, DPM

Foot & Ankle Surgery · Potomac, MDNPI 1881697886

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Treace Medical Concepts, Inc. at 51.6% of the total. Among foot & ankle surgery clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$67,700in general payments, 2019–2025

Across 248 payments — averaging $272.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$35K
  • AbbVie$17K
  • Convatec Inc.$4K
  • Arteriocyte Medical Systems, Inc.$3K
  • Biotissue Holdings Inc.$1K
  • In2bones USA, LLC$1K
  • plus $6K from 34 others

What the payments were for

  • Consulting fees$30,45045%
  • Speaking & faculty fees$18,32527%
  • Travel & lodging$6,50010%
  • Food & beverage$8,10412%
  • Education$1210%
  • Other$4,2006%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,700 in reported general payments places this provider in the 90th percentile of 182 foot & ankle surgery providers in Maryland.

See all foot & ankle surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$303,197
Medicare patients
582
Services billed
3,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole13$19,145
CiclopiroxCiclopirox Olamine48$1,297
Mupirocin67$636
Terbinafine Hcl88$618
Pregabalin13$300
Gabapentin11$217
Cefadroxil24$204
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$90
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$180$19,14513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 foot & ankle surgery providers in Maryland.

Other foot & ankle surgery in Potomac

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →